Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2026-06-28 @ 8:21 PM
Study NCT ID:
NCT02319005
Status:
COMPLETED
Last Update Posted:
2018-07-18
First Post:
2014-12-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor:
Organization:
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:
Phases
| Phase Brief | Phase Text | View |
|---|---|---|
| None | PHASE3 | View |
Observational Models:
Time Perspective List:
Who Masked List: